|Day Low/High||2.20 / 2.39|
|52 Wk Low/High||1.92 / 5.47|
Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales
INO-1800 shows ability to activate and expand CD8+ killer T cells
We’re cleaning house of Three-rated Inovio Pharma and Pixelworks and starting a small position in ancillary cannabis play Kush Bottles.
The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 1,234,538 share increase in total short interest for Inovio Pharmaceuticals Inc. , to 10,650,607, an increase of 13.11% since 01/31/2018.
During a shortened trading week we closed out of one position and added to another after earnings reports.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the April 20th expiration.
We added to several positions on weakness during a challenging last week for the stock market.
We exited one position and added to another as volatility returned to the stock market last week.
It was a mixed week for the portfolio as we trimmed one position and added to the Bullpen.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the March 16th expiration.
Last week, we closed a position for a large gain and used some of the proceeds to start a small stake in a fracking and desalination name.
Dr. David B. Weiner, Inovio co-founder, and Dr. Jian Yan, Lead Antigen Designer, recognized for their innovative medical and scientific research which led to more than 20 granted U.S. patents in one year
Despite a shortened trading week, we made a series of moves, including initiating a position in GSV Capital.
First efficacy trial to evaluate Inovio's cancer immunotherapy targeting HPV in combination with durvalumab
We'll sell some Inovio Pharma on recent strength and put 2 'pot names,' Kush Bottles and Corbus Pharmaceuticals, in the Bullpen.
During a quiet week for the market, we added to two positions and trimmed three others.
Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales
We will buy more AcelRx Pharmaceuticals and sell shares of Inovio Pharmaceuticals as we close out 2017.
During another busy week, we rang the register and exited our position in Amplify, trimmed another name twice and scaled into a recent addition.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.